Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diet composition alters the metabolic states of adipocytes and hepatocytes in diabetes. The effects of dipeptidyl peptidase-4 (DPP-4) inhibition on adipose tissue inflammation and fatty liver have been obscure. We investigated the extrapancreatic effects of DPP-4 inhibition on visceral fat and the liver. RESEARCH DESIGN AND METHODS: We investigated diet-induced metabolic changes in β-cell–specific glucokinase haploinsufficient (Gck+/−) diabetic mice. We challenged animals with a diet containing a combination of sucrose and oleic acid (SO) or sucrose and linoleic acid (SL). Next, we assessed the effects of a DPP-4 inhibitor, des-fluoro-sitagliptin, on adipose tissue inflammation and hepatic steatosis. RESULTS: The epididymal fat weight and serum leptin level were significantly higher in Gck+/− mice fed SL than in mice fed SO, although no significant differences in body weight or adipocyte size were noted. Compared with SO, SL increased the numbers of CD11c+ M1 macrophages and CD8+ T-cells in visceral adipose tissue and the expression of E-selectin, P-selectin, and plasminogen activator inhibitor-1 (PAI-1). DPP-4 inhibition significantly prevented adipose tissue infiltration by CD8+ T-cells and M1 macrophages and decreased the expression of PAI-1. The production of cytokines by activated T-cells was not affected by DPP-4 inhibition. Furthermore, DPP-4 inhibition prevented fatty liver in both wild-type and Gck+/− mice. DPP-4 inhibition also decreased the expressions of sterol regulatory element–binding protein-1c, stearoyl-CoA desaturase-1, and fatty acid synthase, and increased the expression of peroxisome proliferator–activated receptor-α in the liver. CONCLUSIONS: Our findings indicated that DPP-4 inhibition has extrapancreatic protective effects against diet-induced adipose tissue inflammation and hepatic steatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in mice reported a reduction in liver TG and histologic grade of hepatic steatosis with sitagliptin [183] but if this is a direct or indirect effect is uncertain.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [183]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of Huh7 and HepG2 hepatoma cells with exenatide decreased intracellular lipid accumulation [181,182] by enhancing fatty acid oxidation and reducing lipogenesis [160,161,179,183].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [183]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 1×
“A phenotypic switch of ATMs from an anti-inflammatory M2 polarization state to a proinflammatory M1 polarization state is thought to be responsible for the inflammatory changes in the adipose tissue (21,24).”
BackgroundCinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., & Obin, M. S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500294-jlr200 · Cited by 2,529
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Hodson, L., Skeaff, C. M., & Fielding, B. A. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.03.003 · Cited by 1,309
The Opposing Effects of N-3 and n-6 Fatty Acids
Schmitz, G., & Ecker, J. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.12.004 · Cited by 1,245 · cited 1×
“Linoleic acid is converted to arachidonic acid in vivo, and arachidonic acid is converted to prostaglandins, leukotrienes, and other lipid mediators by lipoxygenase or cyclooxygenase (38).”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Advances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Glucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092 · cited 1×
“The combination of high levels of dietary sugars and fatty acids causes metabolic abnormalities in multiple organs (1,2).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Because GIP receptor-deficient mice had a lower weight and a lower adiposity (43), it seems unlikely that the increase in active GIP arising from the inhibition of DPP-4 caused a reduction in visceral fat.”
Background
Cited by
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
The pathophysiology of hypertension in patients with obesity
DeMarco, V. G., Aroor, A. R., & Sowers, J. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.44 · Cited by 545
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
“Although adipose tissue biopsies were not performed as part of our study protocol, reductions in adipose tissue inflammation have been observed in rodents treated with DPP-IV inhibitor that increase endogenous GLP-1 levels [12].”
BackgroundMethodFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
Modulation of adipose tissue inflammation by bioactive food compounds
Siriwardhana, N., Kalupahana, N. S., Cekanova, M., LeMieux, M., Greer, B., & Moustaid-Moussa, N. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.12.013 · Cited by 345
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance
Aroor, A. R., McKarns, S., DeMarco, V. G., Jia, G., & Sowers, J. R. (2013) · Metabolism · doi:10.1016/j.metabol.2013.07.001 · Cited by 242
Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 233
Adipose Dipeptidyl Peptidase-4 and Obesity
Sell, H., Blüher, M., Klöting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W. T., Dietrich, A., Fielding, B. A., Arner, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0496 · Cited by 218
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Fadini, G. P., & Avogaro, A. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.05.001 · Cited by 213
Zhong, J., Rao, X., & Rajagopalan, S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.012 · Cited by 208
Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., & Aso, Y. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0169-x · Cited by 202
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Zhuge, F., Ni, Y., Nagashimada, M., Nagata, N., Xu, L., Mukaida, N., Kaneko, S., & Ota, T. (2016) · Diabetes · doi:10.2337/db16-0317 · Cited by 191
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Dipeptidyl peptidase-4: A key player in chronic liver disease
Itou, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i15.2298 · Cited by 177
A 360-degree overview of paediatric NAFLD: Recent insights
Nobili, V., Svegliati-Baroni, G., Alisi, A., Miele, L., Valenti, L., & Vajro, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.003 · Cited by 171
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 207
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz, G. (2014) · PubMed · doi:10.3748/wjg.v20.i27.9072 · Cited by 147
Innate immune activation in obesity
Lumeng, C. N. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.002 · Cited by 142
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Yaribeygi, H., Katsiki, N., Butler, A. E., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.005 · Cited by 140
Yokomizo, H., Inoguchi, T., Sonoda, N., Sakaki, Y., Maeda, Y., Inoue, T., Hirata, E., Takei, R., Ikeda, N., Fujii, M., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00688.2013 · Cited by 132
Self-citationEffect of Vildagliptin on Hepatic Steatosis
Macauley, M., Hollingsworth, K. G., Smith, F. E., Thelwall, P. E., Al-Mrabeh, A., Schweizer, A., Foley, J. E., & Taylor, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3794 · Cited by 128
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Glucagon-like peptide-1 (GLP-1) is an endogenous incretin secreted by small intestinal L cells, consisting of two bioactive isoforms: GLP-1 (7-37) and GLP-1 (736).”
BackgroundNonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
Schattenberg, J. M., & Schuppan, D. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834c7cfc · Cited by 119
CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
Lee, S. A., Kim, Y. R., Yang, E. J., Kwon, E.-J., Kim, S. H., Kang, S. H., Park, D. B., Oh, B.-C., Kim, J., Heo, S. T., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4288 · Cited by 116
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
Kern, M., Klöting, N., Niessen, H. G., Thomas, L. H., Stiller, D., Mark, M., Klein, T., & Blüher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038744 · Cited by 117
Adipose tissue, diet and aging
Zamboni, M. M., Rossi, A. P., Fantin, F., Zamboni, G. A., Chirumbolo, S., Zoico, E., & Mazzali, G. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.11.008 · Cited by 133
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 107
Adipose Tissue‐Derived Plasminogen Activator Inhibitor‐1 Function and Regulation
Kaji, H. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160004 · Cited by 117
Packer, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 100
Cardiovascular effects of the DPP-4 inhibitors
Jose, T., & Inzucchi, S. E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111436236 · Cited by 93
Can metabolically healthy obesity be explained by diet, genetics, and inflammation?
Navarro, E., Funtikova, A. N., Fitó, M., & Schröder, H. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400521 · Cited by 100
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 94
Significance of circulatory DPP4 activity in metabolic diseases
Nargis, T., & Chakrabarti, P. (2018) · IUBMB Life · doi:10.1002/iub.1709 · Cited by 80
Understanding the cause of type 2 diabetes
Taylor, R. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00157-8 · Cited by 95
Filozof, C., Goldstein, B. J., Williams, R. N., & Sanyal, A. (2015) · Drugs · doi:10.1007/s40265-015-0437-3 · Cited by 77
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Öztürk, Z. A., & Kadayıfçı, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i4.199 · Cited by 85
Aroor, A. R., Habibi, J., Ford, D. A., Nistala, R., Lastra, G., Manrique, C., Dunham, M. M., Ford, K. D., Thyfault, J. P., Parks, E. J., et al. (2015) · Diabetes · doi:10.2337/db14-0804 · Cited by 76
Hwang, H.-J., Jung, T. W., Kim, B.-H., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., Baik, S. H., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.098 · Cited by 72
Yaribeygi, H., Atkin, S. L., Pirro, M., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27699 · Cited by 72
Lee, D., Lee, E.-S., Alam, M. M., Jang, J.-H., Lee, H.-S., Oh, H., Kim, Y., Manzoor, Z., Koh, Y., Kang, D.-G., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.002 · Cited by 70
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Klein, T., Fujii, M., Sandel, J. P., Shibazaki, Y., Wakamatsu, K., Mark, M., & Yoneyama, H. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0053-9 · Cited by 71
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59
“Liver and adipose tissue samples were formalin fixed and paraffin embedded, and Masson-Goldner staining (Merck Research Laboratories, Lahway, NJ) and F4/80 antibody (Serotec, Oxford, UK) staining were performed as described previously (25, 31).”
MethodSelf-citationShinjo, T., Nakatsu, Y., Iwashita, M., Sano, T., Sakoda, H., Ishihara, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Tsuchiya, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00553.2014 · Cited by 59
Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition
Nistala, R., Habibi, J., Lastra, G., Manrique, C. M., Aroor, A. R., Hayden, M. R., Garro, M., Meuth, A. I., Johnson, M. S., Whaley‐Connell, A. T., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1920 · Cited by 63
Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Barchetta, I., Cimini, F. A., Dule, S., & Cavallo, M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10092306 · Cited by 55
Pezhman, L., Tahrani, A. A., & Chimen, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.624184 · Cited by 69
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sanchez, P., & Cusi, K. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 56
Xu, J., Wang, J., He, M., Han, H., Xie, W., Wang, H., & Kong, H. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0080-1 · Cited by 58
Williams, K., de Ribeiro, A. J. V., Prakoso, E., Veillard, A., Shackel, N. A., Brooks, B. A., Bu, Y., Cavanagh, E., Raleigh, J., McLennan, S. V., et al. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12237 · Cited by 53
Shirakawa, J., Amo, K., Ohminami, H., Orime, K., Togashi, Y., Ito, Y., Tajima, K., Koganei, M., Sasaki, H., Takeda, E., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217216 · Cited by 59
Self-citationShimasaki, T., Masaki, T., Mitsutomi, K., Ueno, D., Gotoh, K., Chiba, S., Kakuma, T., & Yoshimatsu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063626 · Cited by 52
Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
Kubota (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1061w · Cited by 55
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Bae, E. J. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0813-x · Cited by 62
Cusi, K. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
Noureddin, M., Muthiah, M. D., & Sanyal, A. J. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.105 · Cited by 52
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
Sakamoto, E., Seino, Y., Fukami, A., Mizutani, N., Tsunekawa, S., Ishikawa, K., Ogata, H., Uenishi, E., Kamiya, H., Hamada, Y., et al. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00208.x · Cited by 51
Self-citationSalim, H. M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.03.003 · Cited by 53
Ojeda, M. J., Gimeno, A., Tomas‐Hernández, S., Cereto‐Massagué, A., Beltrán‐Debón, R., Valls, C., Mulero, M., Pujadas, G., & García-Vallvé, S. (2018) · Medicinal Research Reviews · doi:10.1002/med.21499 · Cited by 55
Aroor, A., McKarns, S., Nistala, R., DeMarco, V., Gardner, M., Garcia-Touza, M., Whaley-Connell, A., & Sowers, J. R. (2013) · Cardiorenal Medicine · doi:10.1159/000348756 · Cited by 49
Liu, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 49
The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation
Neff, K., Frankel, A., Tam, F. W. K., Sadlier, D. M., Godson, C., & le Roux, C. W. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft262 · Cited by 51
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 50
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Wang, X., Zheng, P., Huang, G., Yang, L., & Zhou, Z. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0519-0 · Cited by 51
Kawaguchi, T., Nakano, D., Koga, H., & Torimura, T. (2018) · Liver Cancer · doi:10.1159/000491763 · Cited by 49
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Avogaro, A., Kreutzenberg, S., & Fadini, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990474 · Cited by 45
Potential of incretin-based therapies for non-alcoholic fatty liver disease
Samson, S. L., & Bajaj, M. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.005 · Cited by 47
Inoue, H., Shirakawa, J., Togashi, Y., Tajima, K., Okuyama, T., Kyohara, M., Tanaka, Y., Orime, K., Saisho, Y., Yamada, T., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809228 · Cited by 50
Self-citationFocus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
Federico, A., Zulli, C., de Sio, I., Prete, A. D., Dallio, M., Masarone, M., & Loguercio, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16841 · Cited by 50
Lu, H. Y., Huang, C., Shih, C. M., Chang, W. H., Tsai, C.-S., Lin, F., & Shih, C. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121077 · Cited by 47
Nam, Y. R., Won, S. B., Chung, Y.-S., Kwak, C. S., & Kwon, Y. H. (2015) · Nutrition Research and Practice · doi:10.4162/nrp.2015.9.3.235 · Cited by 44
Famulla, S., Schlich, R., Sell, H., & Eckel, J. (2012) · Adipocyte · doi:10.4161/adip.19962 · Cited by 43
Mega, C., Teixeira‐Lemos, E., Fernandes, R., & Reis, F. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5164292 · Cited by 38
Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126578 · Cited by 45
Zhao, J., Zhao, Y., Hu, Y., & Peng, J. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00276-7 · Cited by 44
DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo
Ishida, M., Shen, W.-R., Kimura, K., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., Ohori, F., Noguchi, T., Marahleh, A., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.052 · Cited by 36
Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Rizzo, M., Nikolić, D., Banach, M., Patti, A. M., Montalto, G., & Rizvi, A. A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131206102255 · Cited by 36
Uchida, T., Oda, T., Matsubara, H., Watanabe, A., Takechi, H., Oshima, N., Sakurai, Y., & Kumagai, H. (2017) · Renal Failure · doi:10.1080/0886022x.2017.1279553 · Cited by 37
Effects of Sitagliptin on Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Rats
Beysel, S., Değertekin, C. K., Yılmaz, G., Çakır, N., Arslan, M., & Törüner, F. B. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0128 · Cited by 36
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Janardhan, S., & Sastry, G. N. (2014) · Current Drug Targets · doi:10.2174/1389450115666140311102638 · Cited by 39
Hussain, M., Babar, M. Z. M., Hussain, M. S., & Akhtar, L. (2016) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.326.11133 · Cited by 39
Aroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 38
Derosa, G., Carbone, A., D'Angelo, A., Querci, F., Fogari, E., Cicero, A. F. G., & Maffioli, P. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8175 · Cited by 35
Promising therapies for treatment of nonalcoholic steatohepatitis
Noureddin, M., Zhang, A., & Loomba, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220533 · Cited by 37
Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 35
Saxagliptin regulates M1/M2 macrophage polarization via CaMKKβ/AMPK pathway to attenuate NAFLD
Yang, Y., Lu, Y., Han, F., Chang, Y., Li, X., Han, Z., Xue, M., Cheng, Y., Sun, B., & Chen, L. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.090 · Cited by 35
Yano, W., Inoue, N., Ito, S., Ito, T., Yasumura, M., Yoshinaka, Y., Hagita, S., Goto, M., Nakagawa, T., Inoue, K., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12593 · Cited by 35
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
The Role of Medications for the Management of Patients with NAFLD
Mazzella, N., Ricciardi, L. M., Mazzotti, A., & Marchesini, G. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.005 · Cited by 35
Metadata
- Authors
- Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., Amo, K., Aoki, K., Morimoto, C., Takeda, E., & Terauchi, Y.
- Affiliations
- Yokohama City University (JP)
- Keio University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Meiji (Japan) (JP)
- Tokushima University (JP)
- Corresponding author
- Terauchi, Yasuo
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-03-22
- Volume
- 60
- Issue
- 4
- Pages
- 1246-1257
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3064098
- OpenAlex
- W2102849202
- Cited by
- 246
- References
- 49
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 5 · 2022: 11 · 2021: 16 · 2020: 11 · 2019: 13 · 2018: 27 · 2017: 10 · 2016: 26 · 2015: 23 · 2014: 31 · 2013: 29 · 2012: 21
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23591315, 22650223, 22590437, 21300277, 22390200)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- DPP-4 inhibition, adipose tissue inflammation, hepatic steatosis, diet-induced obesity, visceral adipose tissue, M1 macrophages, CD8+ T cells, plasminogen activator inhibitor-1, fatty acid synthase, stearoyl-CoA desaturase 1, SREBP-1c, PPARα, linoleic acid, oleic acid, sucrose, leptin
- MeSH terms
- Exenatide, Adipose Tissue, Animals, Blood Glucose, Body Weight, Dietary Fats, Enzyme-Linked Immunosorbent Assay, Fatty Liver, Female, Glucokinase, Hypertrophy, Insulin, Interferon-gamma, Liver, Male, Peptides, Triglycerides, Tumor Necrosis Factor-alpha, Venoms, Polymerase Chain Reaction, Interleukin-10, Dipeptidyl Peptidase 4, Chemokine CCL2, Dietary Sucrose, Mice, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.